| 1093 |
Prevention of Drug-resistance |
06/09/2022 |
|
| 1859 |
Follow-up Monitoring of DR-TB Patients |
06/09/2022 |
|
| 1568 |
Management of M/XDR-TB Treatment During Pregnancy |
06/09/2022 |
|
| 593 |
Drug-Resistant Tuberculosis(DR-TB) |
06/09/2022 |
|
| 1296 |
Maintenance of the Truenat Instrument - General Principles |
08/09/2022 |
|
| 3191 |
PMDT structure and roles |
09/09/2022 |
|
| 3192 |
Referral mechanisms for DR-TB services |
09/09/2022 |
|
| 3195 |
ICTC |
09/09/2022 |
|
| 3197 |
Link ART Centre |
09/09/2022 |
|
| 3199 |
PMDT Treatment Book |
09/09/2022 |
|
| 3200 |
TB Comorbidity Committee |
09/09/2022 |
|
| 3204 |
National TB-HIV Collaborative Framework |
09/09/2022 |
|
| 3206 |
NACP and NTEP Coordination at National, State and District Levels |
09/09/2022 |
|
| 3207 |
State AIDS Control Society [SACS] |
09/09/2022 |
|
| 3209 |
Linkage to TB-HIV services in the private sector |
09/09/2022 |
|
| 3211 |
HIV testing of presumptive TB cases and TB patients |
09/09/2022 |
|
| 3212 |
Tuberculosis Health Action Learning Initiative [THALI] |
09/09/2022 |
|
| 3214 |
Intensified TB Case Finding [ICF] in HIV testing Settings |
09/09/2022 |
|
| 3240 |
Reconstitution Register |
09/09/2022 |
|
| 3243 |
PMDT Review Mechanisms |
09/09/2022 |
|
| 3258 |
Treatment of DS-TB with HIV Coinfection |
09/09/2022 |
|
| 3248 |
Ni-kshay HIV Status Report |
09/09/2022 |
|
| 3249 |
Quarterly report on TB-HIV Collaborative Activities |
09/09/2022 |
|
| 3250 |
Performance Indicators and Targets for TB-HIV Collaborative Activities |
09/09/2022 |
|
| 3251 |
TB-HIV joint review mechanisms |
09/09/2022 |
|
| 3253 |
Role of the DR-TB HIV Coordinator in treatment centres |
09/09/2022 |
|
| 3257 |
Treatment of DR-TB with HIV Coinfection |
09/09/2022 |
|
| 3260 |
Isoniazid Preventive Therapy [IPT] in People Living with HIV [PLHIV] |
09/09/2022 |
|
| 3262 |
Prevention of TB in facilities caring for HIV-infected persons |
09/09/2022 |
|
| 3279 |
F-ICTC |
12/09/2022 |
|
